Abstract
ObjectiveTo evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have